APP and Cognitive impairment: The latest research showed that long-term TSG (50, 100 mg/kg) treatment significantly improved the cognitive impairment by reducing the deposition of Aβ plaques in the hippocampus and cortex in the APP/PS1 AD mouse model, thereby preventing AD (Gao et al., 2021).